Asia-Pacific Americas Africa Europe Middle East

SHILPA PHARMA LIFESCIENCE LIMITED

Company Profile:

Company Type: Manufacturer

Shilpa Pharma Lifescience Limited is a leading Indian pharmaceutical company. It is primarily a manufacturer, deeply involved in the development, production, and marketing of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms.

The company has built a strong reputation as a key player in the global pharmaceutical landscape, particularly recognized for its expertise in oncology and other complex therapeutic areas. Shilpa Pharma operates advanced manufacturing facilities that meet stringent international regulatory standards, including those set by the US FDA, EU GMP, and other global authorities.

Key characteristics of Shilpa Pharma Lifescience Limited include:

Strong Research and Development (R&D) Focus: The company places significant emphasis on R&D to innovate and develop new APIs, pharmaceutical formulations, and advanced drug delivery systems.

Diverse Product Portfolio: It offers a wide array of products across various therapeutic segments, with a notable presence in oncology, central nervous system (CNS) disorders, and other critical care categories.

Extensive Global Presence: Shilpa Pharma exports its products to numerous regulated and semi-regulated markets across the world.

Commitment to Quality: The company strictly adheres to rigorous quality control measures and Good Manufacturing Practices (GMP) throughout all its operational processes.

In summary, Shilpa Pharma Lifescience Limited functions as a vertically integrated pharmaceutical manufacturer, possessing capabilities that span from the synthesis of APIs to the development and commercialization of finished pharmaceutical products.

Enterprise Products

SHILPA PHARMA LIFESCIENCE LIMITED manufactures or sells the following products:

Active Pharmaceutical Ingredients (APIs)

Capecitabine

Imatinib Mesylate

Erlotinib Hydrochloride

Lapatinib Ditolsylate

Lenalidomide

Pemetrexed Disodium

Bortezomib

Sunitinib Malate

Aprepitant

Ixabepilone

Everolimus

Dasatinib

Nilotinib

Ruxolitinib

Pazopanib Hydrochloride

Sorafenib Tosylate

Regorafenib

Cabozantinib

Dabrafenib

Crizotinib

Enzalutamide

Osimertinib

Gabapentin

Pregabalin

Paliperidone

Sitagliptin

Dapagliflozin

Finished Dosage Forms (Formulations)

Capecitabine Tablets

Imatinib Mesylate Tablets

Erlotinib Tablets

Lenalidomide Capsules

Pemetrexed for Injection

Bortezomib for Injection

Sunitinib Capsules

Aprepitant Capsules

Everolimus Tablets

Dasatinib Tablets

Nilotinib Capsules

Ruxolitinib Tablets

Pazopanib Tablets

Sorafenib Tablets

Regorafenib Tablets

Cabozantinib Tablets

Dabrafenib Capsules

Crizotinib Capsules

Enzalutamide Capsules

Osimertinib Tablets

Pharmaceutical Intermediates

Business Registration Information:

Manager:

Mr. S. Karunakar Reddy

Phone:

+91 8532 237300

E-mail:

info@shilpapharma.com

Official Website:
Address:

12-6-214/A-1, Hyderabad Road, Raichur - 584103, Karnataka, India.

This content is from AI, the data and information provided is for reference only and is not applicable to investment and purchase decisions. If there is any incorrect information, please contact customer service to correct it.